Clinical Trials Logo

Endometrial Cancer clinical trials

View clinical trials related to Endometrial Cancer.

Filter by:

NCT ID: NCT05827614 Recruiting - Breast Cancer Clinical Trials

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications

POTENTIATE
Start date: March 24, 2023
Phase: Phase 1
Study type: Interventional

BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx). This is a first-in-human, open-label, 3-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-355 administered as a single agent or in combination with select therapies.

NCT ID: NCT05824481 Not yet recruiting - Endometrial Cancer Clinical Trials

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, multi-center Phase II study of cadonilimab (AK104) combined with lenvatinib in patients with advanced endometrial cancer. The primary objective is to evaluate objective response rate of cadonilimab plus lenvatinib.

NCT ID: NCT05819892 Recruiting - Endometrial Cancer Clinical Trials

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Start date: July 17, 2023
Phase: Phase 1
Study type: Interventional

To learn if chemotherapy given in combination with radiation therapy, followed by maintenance therapy, can help to control endometrial cancer. The safety and effects of this study treatment will also be studied

NCT ID: NCT05812677 Recruiting - Cervical Cancer Clinical Trials

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer

Start date: February 6, 2023
Phase: Early Phase 1
Study type: Interventional

20 participants are expected to be enrolled for this open,Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory Cervical and Endometrial Cancer.

NCT ID: NCT05807672 Recruiting - Endometrial Cancer Clinical Trials

Magnetic Resonance Fingerprinting in the Imaging of Endometrial Cancer

MARF-E
Start date: April 23, 2022
Phase:
Study type: Observational

In this context, the aim of this study is to investigate the role of MRF in endometrial cancer. Several applications are possible. Firstly, T1-, T2- and DWI-mappings can be associated to molecular risk group classification, in order to stratify patients' risk without recurring to surgery. MRF parameters can be also correlated to prognosis, both in terms of disease-free survival (DFS) and overall survival (OS).

NCT ID: NCT05805358 Not yet recruiting - Ovarian Cancer Clinical Trials

Hyperpolarized 13C MRI for Cancer Immunotherapy

DNPSPIO
Start date: November 1, 2023
Phase: Phase 2
Study type: Interventional

The investigators aim to develop an advanced imaging platform, such as dynamic nuclear polarization (DNP) 13C-MRI, MR fingerprinting (MRF) and MR Relaxometry, which combines with traditional anatomical contrast CT, MRI and PET, and integrate blood/urine metabolomics methods. A comprehensive strategy to thoroughly analyze the immune activation of spleen pattern, microstructure, cell density, red blood cell iron content, immune cell glycolysis and metabolic flow rate.

NCT ID: NCT05797831 Recruiting - Endometrial Cancer Clinical Trials

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Start date: July 17, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose compared to placebo.

NCT ID: NCT05796518 Active, not recruiting - Endometrial Cancer Clinical Trials

Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors

Start date: September 7, 2023
Phase: N/A
Study type: Interventional

Investigators are conducting this study to find out more about what heart health means to participants and how healthcare providers can best help to manage heart health. Participants will be asked to view an electronic tool designed to promote heart health awareness and help to manage heart health outside of the clinic. This study will provide important information to help investigators develop future programs that improve cancer patient's heart health after they complete their treatment.

NCT ID: NCT05795244 Recruiting - Endometrial Cancer Clinical Trials

Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)

Start date: October 31, 2023
Phase: Phase 2
Study type: Interventional

phase 2 clinical trial to confirm the pathological complete response rate of PD-1 blocker use in patients with Mismatch Repair Deficiency(MMRd) endometrial cancer that can be completely resected surgically.

NCT ID: NCT05793333 Not yet recruiting - Endometrial Cancer Clinical Trials

Predictors of Node Positivity in Endometrial Cancer

Start date: August 10, 2023
Phase:
Study type: Observational

To investigate the role of histological and moleculr profile of endometrial cancer patietns in predicting the risk of nodal metastases in endoemtrila cancer patients.